Contents

SECTION 1 General Pharmacology

1.1 Introduction and Terminology **3**
Terminology 3; Nomenclature of Drugs 5; Sources of Drugs 5;
Factors Affecting Dosage and Therapeutic Response 6;
Effects of Drug Interactions 8; Drug Therapy Monitoring 9;
Legislation Regarding Narcotic Drugs 9; Drug Dosage Calculations 10;
Biotransportation of Drugs 10; Drug Absorption 12;
Drug Distribution 15; Drug Metabolism 16; Pediatric Pharmacology 18;
Geriatric Pharmacology 18; Pharmacogenetics 19;
Other Examples of Genetic Mutations Affecting Drug Responses 21;
Pediatric (Neonate to About 16 Years) 22; Geriatric (Aged Above 65 Years) 23;
Women 23; Enzyme Inhibition 26; Drug Receptor Interactions 27

1.2 Routes of Drug Administration **31**
Enteral Route 31; Parenteral Route 36; Nasal Route 40;
Cutaneous or Transdermal Route 41; Topical (Local) Route 41;
Other Routes 42; Particular Preparations 43; Bioavailability 43;
Bioequivalance 43

1.3 Pharmacokinetics and Pharmacodynamics **45**
Pharmacokinetics 45; Pharmacodynamics 51

1.4 Biotransformation of Drugs **59**
Drug Metabolism 59

SECTION 2 Drugs Affecting Autonomic Nervous System

2.1 Autonomic Nervous Systems **67**
Nervous Systems 67; Neurotransmitters 70;
Cholinergic Receptors 73; Effects of Drugs 76

2.2 Adrenergic Drugs **79**
Adrenergic Receptors 79; Adrenergic Stimulants (Agonists) 84;
Summary of Clinical Uses of Sympathomimetic Agents 99;
Adrenergic Antagonists (Blockers) 100; Drugs Affecting
Neurotransmitter Release or Uptake 108;
Conditions that Resemble Myasthenia Gravis 110

2.3 Cholinergic Drugs **113**
Cellular Events Following Cholinergic Receptor Activation 114;
Second Messenger Systems 115;
Stimulation of Cholinergic Receptors 116;
Antagonists (Inhibition) of Cholinergic Receptors 126

2.4 Antimyasthenic Drugs **135**
Classification of Antimyasthenic Drugs 136

SECTION 3 Drugs Affecting Central Nervous System

3.1 Central Nervous System **143**
Neurotransmitters 143; Central Nervous System Stimulants 147;
Antidepressant 148; Hallucinogenic Drugs 150;
Central Nervous System Depressants—Sedative and Hypnotic Agents 151;
Narcotic Analgesic Drugs 153; Narcotic Antagonists 156;
Local Anesthetics 157

3.2 Anxiolytics and Sedative–Hypnotics **159**
Classification of Anxiolytics and Hypnotic Drugs 159;
Pharmacokinetics 160; Major Hypnotic Drug Classes 166;
Benzodiazepine Antagonist 168

3.3 Antiepileptics **171**
Epilepsy 171; Antiepileptic Agents 173;
Special Considerations for Starting Antiepileptic Therapy 181

3.4 General Anesthetics **185**
Classification of drugs used for General Anesthesia 185;
Procedure for General Anesthesia 186; Stages of Anesthesia 191;
Causes of Mortality 193; Intravenous Anesthetics 194;
Inhalation Anesthetics 197

3.5 Local Anesthetics **203**
Classification of Local Anesthetics 204; Properties 205;
Mechanism of Action of Local Anesthetics 206;
Pharmacokinetics 206; Effects of Local Anesthetics 207; Preparations 210;
Clinical Uses of Local Anesthetics 211

3.6 Parkinson's Disease **219**
Clinical Manifestations 220;
Medications for Parkinson's Disease 220

3.7 Skeletal Muscle Relaxants **229**
Spasticity 230; Spasmolytic Agents 230; Neuromuscular Blocking Agents 235;
Non-depolarizing Neuromuscular Blocking Agents 241;
Depolarizing Neuromuscular Blocking Drugs 247; Skeletal Muscle Spasm 250;
Clinical Pharmacology of Neuromuscular-blocking Agents 254;
Reversal of Neuromuscular Blockade by Antagonist 254

3.8 Antipsychotic Drugs 259
Schizophrenia 259; Classification of Antipsychotic Drugs 260;
Clinical Uses of Antipsychotics 261; Antimanic Agents 266

3.9 Central Nervous System Stimulants and Antidepressants 273
Stimulants of Central Nervous System 273;
Serotonin Antagonists 278; Antidepressant Agents 280

3.10 Opioid Analgesic and Antagonists 291
Distribution of Opioid Receptors and their Influence 291;
Classification of Opioids 292; Effect of Opioid Analgesics on the Central Nervous System 294;
Pharmacokinetics 295; Pharmacodynamics 296; Neurochemistry of Pain 297;
Organ System Effects of Opioids 298; Organ System Effects of Pentazocine
and other Agonist-antagonists 301; Clinical Uses 303;
Specific Drugs 306; Opioid Antagonists (Pure Antagonists) 308

3.11 Ergot Alkaloids 311
Classification 311; Organ Systems Effected by Ergot Alkaloids 311;
Migraine 313

3.12 Alcohols 323
Important Commonly Encountered Alcohols 323;
Effects of Alcohol 324; Pharmacokinetics 327;
Alcohol Abuse 328; Methanol Abuse 330

3.13 Drug Abuse 331
Medical Definitions 331; Signs and Symptoms 332; Drug Abuse 333

SECTION 4 Drugs Acting on Cardiovascular and Renal System

4.1 Antihyperlipidemic Agents 339
Lipoprotein Metabolism 339;
Strategies for Treating Hyperlipidemias 341

4.2 Anticoagulants 347
Anticoagulant Drugs 347; Classification of Anticoagulants 347;
Clinical Uses of Anticoagulants 349; Recommended Dosage 350;
Precautions 351; Untoward Effects 351; Interactions 351

4.3 Thrombolytic Drugs 353
Thrombolytic Therapy 353

4.4 Antiplatelet Drugs 359
Aspirin 359; Thienopyridines 361; Glycoprotein IIb/IIIa Receptor Antagonists 363;
Other Antiplatelet Drugs 363

4.5 Antiarrhythmic Drugs 365
Therapeutic Use 366; Mechanism of Action 366;
Classes of Drugs used to Treat Arrhythmias 367

4.6 Vasoactive Drugs **381**
Vasodilators 381; Pressor Drugs 389; Vasoconstrictors 389

4.7 Cardioinhibitory Drugs **395**
Therapeutic Uses of Cardioinhibitory Drugs 395;
Drug Classes and General Mechanisms of Action 396

4.8 Cardiostimulatory Drugs **403**
Therapeutic Use of Cardiostimulatory Drugs 403;
Drug Classes and General Mechanisms of Action 405

4.9 Diuretics **409**
Formation of Urine 409; Therapeutic Uses 411;
Types of Diuretics 412

4.10 Antihypertensive Drugs **427**
Hypertension 427; Rationale of Reducing Arterial Pressure 427;
Antihypertensive Drugs 428; Sympatholytics 431;
Angiotensin Converting Enzyme Inhibitors 434

4.11 Antianginal Drugs **439**
Angina 439; Nitrates 442; β-blockers 446; Potassium-channel Openers 449;
Myocardial Infarction 450

4.12 Cardiac Glycosides **455**
Mechanism of Action 455; Pharmacological Actions 456;
Toxicity of Digitalis 459; Contraindications to Digitalis Therapy 459;
Drug Interactions 460; Clinical Uses 460; Ouabain 461

SECTION 5 Endocrine Drugs

5.1 Hypothalamic and Pituitary Hormones **467**
Hypothalamus 467; Pituitary Gland 468; Pituitary Hormones 470

5.2 Thyroid and Antithyroid Drugs **493**
Thyroid Hormones 493; Antithyroid Drugs 496; Thyroid Hormone Deficiency 499

5.3 Adrenocorticosteroids and their Antagonists **509**
Adrenal Gland 509; Adrenocorticosteroids 510; Indications for Corticosteroids 520;
Antagonists of Adrenocortical Agents 527

5.4 Insulin **533**
Insulin 533; Glucagon 537; Insulin Therapy 540;
Oral Hypoglycemics Agents 548

5.5 Gonadal Hormones and their Inhibitors **561**
Gonadal Hormones 561; Ovary 561; Estrogens 565; Progestins 571;
Other Ovarian Hormones 573; Hormonal Contraception 575;
Estrogen/Progesterone Inhibitors and Antagonists 582;
Other Ovarian Inhibitors 585; Ovulation-inducing Drugs 585;
Testes 587

5.6 Agents Affecting Bone Mineral Homeostasis **595**
Intestinal Absorption 597; Calcium Metabolism 598;
Phosphate Metabolism 598; Fluxes of Calcium and Phosphate 599;
Hormonal Control Systems 600; Osteoporosis 606

SECTION 6 Drugs used to Treat Diseases of Blood

6.1 Drugs used in Disorders of Coagulation **613**
Mechanism of Blood Coagulation 613; Regulation of Coagulation and Fibrinolysis 615;
Anticoagulant Drugs 616; Pharmacological Management of Thrombosis 620;
Drugs used in Bleeding Disorders 622

6.2 Drugs used in Diseases of Hematopoietic System **627**
Anemia 627; Drugs Affecting Hematopoietic System 631

SECTION 7 Drugs Affecting Other Systems

7.1 Pulmonary Pharmacology: Asthma **641**
Definition of Asthma 641; Diagnosis 642; Long-term Control 643;
Quick Relief of Symptoms or Exacerbations Symptoms 644;
Drugs used in the Treatment of Asthma 644; Medicines that Loosen Lung Secretions 655;
Postnasal Drip 657

7.2 Gastrointestinal Drugs **661**
Acid-peptic Diseases 661; Gastric Physiology 661;
Drugs used in Acid-peptic Disease 663;
Antidiarrheal Drugs 670; Laxatives 672; Gastrokinetic (Prokinetic) Agents 674;
Antiemetic Drugs 675

7.3 Anthelmintic Drugs **681**
Chemotherapy of Helminthic Infections 681; Drugs for the Treatment of Nematodes 682;
Drugs for the Treatment of Cestodes 684; Drugs for the Treatment of Trematodes 686;
Drugs for the Treatment of Trematodes and Cestodes 687;
Drugs for the Treatment of Filariasis 687

SECTION 8 Chemotherapeutic Drugs

8.1 Antibacterial Drugs **693**
Classification 694; Proposed Common Mechanism of Bactericidal Antibiotics 699;
Cephalosporins 703; Other β-lactam Containing Antibacterials 705;
Other Inhibitors of Cell Wall Synthesis 706; Aminoglycosides 710;
Chloramphenicol, Tetracyclines and Clindamycin 714; Macrolides 716;
Disrupters of Nucleic Acid Synthesis 718; Sulfa Drugs 721;
Bacterial Resistance to Antibiotics 724;
Cationic Peptides 724

8.2 Antimycobacterial Agents **729**
Tuberculosis 729; Antitubercular Drugs 730; Clinical Uses 730;
Classification 730; Rationale and Evidence for the Standard Regimen 736;
Drug-resistant Tuberculosis 737; Tuberculosis of the Central Nervous System 737;
Use of Steroids in Treating Tuberculosis 737

8.3 Antiviral Drugs **739**
Action of Antiviral Drugs on Life Cycle of Virus 740;
Limitations of Vaccines 741;
Highly Active Antiretroviral Therapy 746;
Treatment of Pneumonia in AIDS 754

8.4 Antifungal Drugs **757**
Fungal Infections 757; Systemic Antifungal Drugs for Systemic Mycoses 758;
Drugs for Cutaneous Mycoses 764; Topical Drugs 766;
Fungal Infections in HIV 766

8.5 Antiprotozoal Drugs **769**
Antimalarial Drugs 769; Parasitic Life Cycle 770;
Classification of Antimalarial Drugs 770;
Classification Based on Site of Drug Action and Parasite Life Cycle 770;
Malaria Chemoprophylaxis 771; Treatment of Malaria 771;
Drugs Against *Pneumocystis Jirovecii* 779; Drugs Against Trichomoniasis 781;
Antiamebic Drugs 781; Drugs Against Leishmaniasis 786;
Drugs Against Giardiasis 788;
Chemotherapy for Toxoplasmosis 789

8.6 Urinary Antiseptics **791**
Nitrofurantoin (Furadantin, Macrobid, Macrodantin, Nitro Macro and Urantoin) 791;
Nalidixic Acid (Nevigramon, Neggram, Wintomylon) 793

8.7 Cancer Chemotherapy **795**
Goal of Cancer Chemotherapy 795;
Problems with Cancer Chemotherapy 796;
Immunological Aspects of Cancer Chemotherapy 796;
Categories of Chemotherapy Drugs 797;
Indications for Chemotherapy 798; Antimetabolites 798; Alkylating Agents 801;
Antibiotics 805; Mitotic Disruptors 807; Enzyme Anticancer Agent 809;
Hormones 810; Hormones Antagonists 811;
Monoclonal Antibodies 813; Others 814;
Cell Cycle Specific Chemotherapeutic Drugs 815

8.8 Drugs Affecting the Immune System **819**
T Helper 1—Cell-mediated Immunity 819;
Inappropriate Immune Response 820;
Antibody Reagents 823; Immunosuppressants 829;
Immunomodulators 833

SECTION 9 Anti-inflammatory and Analgesic Drugs

9.1 Anti-inflammatory Drugs **839**
Classification of Anti-inflammatory Drugs 840;
Non-steroidal Anti-inflammatory Drugs 840

9.2 Antirheumatic Drugs **853**
Methotrexate 853; Chloroquine and Hydroxychloroquine 855;
Tumor Necrosis Factor-alpha Blocking Drugs 855; Gold Compounds 856;
Penicillamine 857; Sulfasalazine 857;
Glucocorticoids 858

9.3 Drugs for Gout **859**
Gout 859; Classification of Drugs used in Gout 860

Index *865*